[Music] Hey, I'm Kramer. Welcome to Mad Money. Welcome to Craig Friends.I'm just trying to make you a little money. My job is not just to entertain you. It's to put it in context.So call me 1 800 743 CBC Jim Kramer. Sometimes you just can't pin a market down. You see things that are so solid, real companies doing real things and getting rewarded for them.Then you see other companies, small cap companies that are being pushed higher by hedge funds and social media with stocks that have no business going high ...

Market Overview - The market showed resilience despite uncertainties regarding trade policy, tariffs, and the Federal Reserve chair [6] - S&P 500 closed up about 01% [6] - Nasdaq was down about 04% due to weakness in big cap tech names [7] - Dow Jones Industrial Average added 04% [7] - Russell 2000 outperformed, with small caps gaining tailwind [7] Earnings and Performance Highlights - Homebuilders outperformed, with the S&P composite 1500 homebuilding index up about 10% [2] - D R Horton's stock was up about 16% after third-quarter earnings beat expectations [18] - PulteGroup's stock was up 12% after reporting better-than-expected earnings [19] - Texas Instruments' second-quarter EPS was $141, beating the consensus estimate of $135, but the stock was down about 7% in after-hours trading [10][12] - Intuitive Surgical's second-quarter revenue came in at $244 billion, and adjusted EPS beat estimates at $22 billion, with shares initially moving higher but later declining [20][29] - Capital One's second-quarter adjusted EPS was $548, far exceeding the consensus estimate of $388, with net revenue at $1249 billion [22][23] - Enphase Energy's second-quarter adjusted EPS beat estimates by $006, and revenue came in better than forecast at $3632 million, with the stock up about 8% in after-hours trading [26] Company Specifics - Texas Instruments invested $39 billion in R&D and CIGNA and invested $49 billion in CapEx and returned $67 billion to owners over the past 12 months [14] - Intuitive Surgical's Da Vinci surgical system installed base grew to 10488 systems as of June 2025, a 14% increase compared to June 30th, 2020 [30] - Capital One's loans held for investment were approximately $4393 billion [23]

Core Insights - Microbot Medical Inc. has appointed Christina Bailey as the new Vice President of Sales, bringing 20 years of medical device sales experience and a successful track record in leading commercial teams [1][2][3] - The company is preparing for the anticipated launch of its LIBERTY Endovascular Robotic System, which is currently pending FDA 510(k) clearance and not available for sale in the U.S. [3][4] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system aimed at overcoming traditional barriers to advanced robotic systems [4] Leadership and Experience - Christina Bailey has held various sales leadership roles at notable companies such as Boston Scientific, Abbott, Stryker, and Intuitive Surgical, equipping her with insights to drive growth and innovation [2] - Her previous role as Vice President of US Sales at Endologix involved building and scaling sales teams and achieving significant sales milestones [2]

Core Insights - The latest PatentVest Pulse report highlights a significant shift in the surgical robotics market, indicating it is not saturated despite the low percentage of robotic surgeries performed globally [1][2] - The report analyzes over 18,000 patent families and $4 billion in M&A activity, focusing on 28 robotic platforms, emphasizing the importance of platform defensibility in the sector [1][3] Industry Overview - Surgical robotics is characterized by fewer than 6% of the 310 million surgeries performed globally involving robots, attributed to cost, complexity, and deployment constraints rather than clinical limitations [2] - The report identifies strategic signals for future category leaders, including IP positioning, regulatory momentum, and platform scalability [3] Company Dynamics - Major surgical robotics platforms like Mako, Monarch, and Hugo began as venture-backed companies with strong IP and regulatory momentum, suggesting potential future leaders are among current emerging companies [5] - Intuitive Surgical remains dominant in the market but is experiencing slower expansion compared to challengers who are outpacing it in new patent filings [8] - Legacy companies such as Medtronic, Johnson & Johnson, and Stryker maintain strong commercial infrastructures, while public challengers like Vicarious Surgical and Microbot Medical are advancing their platforms [8] - Venture-backed companies are aligning for strategic scale, mirroring profiles of past M&A targets, indicating a trend towards consolidation in the industry [8]

Time for Yahoo Finance's market minute. Stocks are mixed as investors hope USChina trade talks will ease tariff tensions. High level talks expected to take place in London today.President Trump reportedly allowing negotiators to weigh lifting export controls according to reports from the Wall Street Journal. Shares of Robin Hood slumping as hopes of the company joining the S&P 500 dash. S&P Dow Jones indices announcing it won't make changes to the benchmarks after doing its quarterly rebalancing.Analysts at ...

Core Viewpoint - TELA Bio, Inc. has appointed Jeffrey Blizard as President to enhance its leadership team and drive the next phase of growth in the medical technology sector, particularly in soft-tissue reconstruction solutions [1][2]. Leadership Changes - Jeffrey Blizard, previously on TELA Bio's Board of Directors, brings extensive industry experience and a successful track record from his role as Global Head of Surgical Sales at Abiomed, contributing to significant growth in that division [1][2]. - The CEO of TELA Bio, Antony Koblish, emphasized that Blizard's leadership will enhance the company's competitive edge and commercial performance in a dynamic market [2]. Company Overview - TELA Bio, Inc. is focused on innovative technologies for soft-tissue reconstruction, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [3]. - The company is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing reliance on permanent synthetic materials [3].

Core Viewpoint - Tesla's market capitalization is currently $888 billion, reflecting a year-to-date drop of 38%, attributed to vehicle quality issues and CEO Elon Musk's controversial actions [1] Group 1: Tesla's Current Situation - Tesla's brand and reputation have suffered, potentially impacting stock growth over the next decade [2] - The company reported revenue of $98 billion for the year, which is lower than BYD's record revenue of $107 billion [4] Group 2: Competitors with Growth Potential - BYD, a Chinese clean energy vehicle manufacturer, has a market value of $162 billion and reported a 29% year-over-year revenue increase in 2024 [5] - BYD delivered 4.25 million vehicles last year, nearly matching Ford's output [4] - If BYD's market value grows at 20% annually, it could reach approximately $1 trillion in a decade, and at 25%, it could approach $1.5 trillion [5] Group 3: Intuitive Surgical - Intuitive Surgical, a leader in robotic surgical equipment, has a market value of around $182 billion and reported a 25% year-over-year revenue increase [6] - The company installed 493 da Vinci surgical systems in the last quarter, increasing its global installed base by 15% [6] - If Intuitive Surgical's market value grows at 20% over the next decade, it could reach $1.1 trillion [8] Group 4: Berkshire Hathaway - Berkshire Hathaway has a market value of $1.1 trillion, already surpassing Tesla [9] - The company has seen a total revenue growth of 30% from 2019 to 2024 and has roughly doubled its revenue over the past decade [11] - If Berkshire Hathaway's market value grows by 80% in the next decade, it could reach near $2 trillion [11]

另一类是定位型，如骨科手术机器人和经皮穿刺机器人等。 去年11月，四川华西医院和西藏妇产儿童医院联手完成了全球首例远程单臂单孔机器人手术。 这次手术用时90分钟，跨越了2000多公里距离。 机器人在手术领域的应用日益广泛，曾经的科幻设想正在一步步变为现实。 国产手术机器人，距欧美还有多大差距？ 优势 手术机器人可以被视作手术台上的"辅助驾驶系统"，能够根据预设程序辅助医生进行精准且复杂的手术操作。 目前，手术机器人主要分为两类。 一类是操作型，如业界知名的"达芬奇"手术机器人，控制系统和操作系统连线独立。 达芬奇Si手术机器人 手术机器人的核心是"机器人外科手术系统"，也就是直接面对病患的部分。 该系统主要由操作控制台、手术器械和手术辅助设备三部分组成。 与用手手术相比，手术机器人有什么优势？ 通过操作运动控制台，医生能够实现对手术器械的高精度控制，从而显著提高手术的精准度和稳定性，将手术范围精确到毫米级别，减少人为因素导致的 手术风险。 稳定性在手术中至关重要。 正如漫威电影中的奇异博士所展示的，医生的手必须稳定，不能有丝毫抖动——这一点无疑是手术机器人对比人手的先天优势。 此外，有的手术机器人还额外配备了 ...

Industry Overview - The surgical robotics market is experiencing rapid growth, driven by advances in minimally invasive surgery, with a market value of $11.48 billion in 2024 and a projected compound annual growth rate of 12.4% from 2025 to 2030 [2] - Key growth drivers include the integration of AI, which enhances precision and reduces complications, and the increasing demand for robotic surgeries due to an aging global population [6][7] Major Areas of Growth - Minimally invasive surgery is a significant factor driving the adoption of surgical robotics, providing benefits such as precision, smaller incisions, and faster recovery times across various fields including urology, gynecology, orthopedics, and general surgery [5] - The aging population is increasing the demand for robotic surgery systems, as these systems offer improved precision and lower risks for older patients [7] Company Analysis Intuitive Surgical - Intuitive Surgical's da Vinci surgical system has been a key performance driver since its launch, offering minimally invasive surgery and supporting rapid adoption through an integrated ecosystem [9] - The company has a long-term expected EPS growth rate of 16.1%, with projected revenue growth of 14.4% for 2025 [10] Zimmer Biomet - Zimmer Biomet is focusing on expanding its ROSA Robotics portfolio, which includes systems for knee, hip, and shoulder surgeries, enhancing the surgical experience [11][12] - The company has a projected sales growth rate of 2.6% for 2025, with a favorable current cash flow rate of 3.6% [13] Stereotaxis - Stereotaxis is expanding its global presence and has achieved regulatory approvals for its next-generation robotic system, GenesisX, enhancing its competitive position [14] - The company has a projected sales growth rate of 26.3% for 2025, with a favorable current cash flow rate of 13.1% [15]

Group 1: Amgen - Amgen is positioned for growth with key products like Tezspire for asthma and Tepezza for thyroid eye disease, with ongoing clinical trials and international launches [3][4] - The company reported a 19% year-over-year revenue increase to $33.4 billion, with a solid 7% organic growth [4] - Amgen's pipeline includes promising candidates like MariTide for weight loss and rocatinlimab for eczema, indicating strong long-term performance potential [5] - The company offers a forward dividend yield of about 3%, significantly higher than the S&P 500 average of 1.3%, and has increased its payouts by 201% over the past decade [6] Group 2: Intuitive Surgical - Intuitive Surgical leads in robotic-assisted surgery with its da Vinci surgical system, recently launching the fifth generation of this device, which has seen strong demand [7][9] - The da Vinci 5 features improvements such as greater precision and efficiency, and a Force Feedback technology that enhances surgical accuracy [8] - The company experienced a 25% year-over-year revenue increase to $2.41 billion, with adjusted earnings per share rising from $1.60 to $2.21 [9] - Intuitive Surgical has treated 16 million patients with its systems, with a compound annual growth rate of 17% in procedure volume over the past five years, indicating sustained growth potential [10][11]